

-continued

---

```

<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide

<400> SEQUENCE: 266

```

```

Arg Ser Phe Lys
1

```

```

<210> SEQ ID NO 267
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide

<400> SEQUENCE: 267

```

```

Arg Val Arg Arg
1

```

---

1. A method of enhancing internalization, penetration, or both of a co-composition into or through a cell, tissue, or both, the method comprising:

administering the composition of claim 98 to a subject, wherein the cell, tissue, or both is in the subject, whereby internalization, penetration, or both of the co-composition into or through the cell, tissue, or both is enhanced.

2-3. (canceled)

4. The method of claim 1, wherein the CendR element permeabilizes the cell, tissue, or both.

5-7. (canceled)

8. The method of claim 1, wherein the CendR element is associated with one or more accessory molecules.

9-11. (canceled)

12. The method of claim 8, wherein at least one of the accessory molecules comprises an RGD peptide, iRGD, a Lyp-1 peptide, a NGR peptide, iNGR, an RGR peptide, a HER2 binding peptide, or a combination.

13. The method of claim 8, wherein one or more of the accessory molecules are independently a homing molecule, a targeting molecule, an affinity ligand, a cell penetrating peptide, an endosomal escape molecule, a subcellular targeting molecule, a nuclear targeting molecule, or a combination.

14. The method claim 13, wherein one or more of the accessory molecules are homing molecules.

15-20. (canceled)

21. The method of claim 8, wherein the CendR element selectively homes to a tumor.

22. The method of claim 21, wherein the CendR element selectively homes to tumor vasculature.

23. The method of claim 8, wherein the CendR element selectively homes to lung tissue.

24. The method of claim 8, wherein the CendR element selectively homes to heart tissue.

25. The method of claim 1, wherein the CendR element is an activatable CendR element.

26. The method of claim 25, wherein the activatable CendR element is a protease-activatable CendR element.

27. (canceled)

28. The method of claim 199, wherein the CendR composition and the co-composition are administered to the subject simultaneously.

29. The method of claim 28, wherein the CendR composition and the co-composition are administered to the subject in a single composition comprising the CendR element and the co-composition.

30. The method of claim 199, wherein the CendR composition and the co-composition are administered to the subject in separate compositions.

31. The method of claim 199 6 or 8-27, wherein the CendR composition and the co-composition are administered to the subject at different times.

32. The method of claim 31, wherein the CendR composition and the co-composition are administered to the subject in separate compositions.

33. The method of claim 30, wherein the CendR composition and the co-composition are administered to the subject by separate routes.

34. The method of claim 1, wherein the CendR element and the co-composition are not bound to each other.

35. The method of claim 1, wherein the co-composition comprises a therapeutic agent.

36. The method of claim 1, wherein the co-composition comprises a detection agent.

37. The method of claim 1, wherein the co-composition comprises a carrier, vehicle, or both.

38. The method of claim 1, wherein the co-composition comprises a therapeutic protein, a therapeutic compound, a therapeutic composition, a cancer chemotherapeutic agent, a toxin, a cytotoxic agent, an anti-inflammatory agent, an anti-arthritis agent, a growth factor, a cytokine, a chemokine, a compound that modulates one or more signaling pathways, an antibody, a nucleic acid, a nucleic acid analog, a cell, a virus, a phage, a viral particle, a phage particle, a viral capsid, a phage capsid, a virus-like particle, a liposome, a micelle, a bead, a nanoparticle, a microparticle, a chemotherapeutic agent, a contrast agent, an imaging agent, a label, a labeling agent, an anti-angiogenic agent, a pro-angiogenic agent, or a combination.

39. The method of claim 1, wherein the CendR element is comprised in an amino acid sequence.